{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:16:39Z","timestamp":1793927799102,"version":"4.8.0"},"reference-count":164,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jocd.2023.101440","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T17:49:27Z","timestamp":1698947367000},"page":"101440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Follow-up Bone Mineral Density Testing: 2023 Official Positions of the International Society for Clinical Densitometry"],"prefix":"10.1016","volume":"27","author":[{"given":"Linsey U.","family":"Gani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanika","family":"Sritara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WeiWen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruban","family":"Dhaliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjodh","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocd.2023.101440_bib0001","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s11606-017-4094-y","article-title":"Incidence and predictors of repeat bone mineral densitometry: a longitudinal cohort study","volume":"32","author":"White VanGompel","year":"2017","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0002","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00198-014-2725-2","article-title":"Overuse of short-interval bone densitometry: assessing rates of low-value care","volume":"25","author":"Morden","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0003","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jocd.2019.07.001","article-title":"Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics","volume":"22","author":"Shuhart","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2023.101440_bib0004","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jocd.2019.07.001","article-title":"Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics","volume":"22","author":"Shuhart","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2023.101440_bib0005","series-title":"The RAND\/UCLA appropriateness method user's manual","author":"Fitch","year":"2001"},{"key":"10.1016\/j.jocd.2023.101440_bib0006","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jocd.2019.07.010","article-title":"Repeating measurement of bone mineral density when monitoring with dual-energy X-ray absorptiometry: 2019 ISCD official position","volume":"22","author":"Kendler","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2023.101440_bib0007","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jocd.2023.101440_bib0008","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jbmr.4444","article-title":"Characteristics of long-term femoral neck bone loss in postmenopausal women: a 25-year follow-up","volume":"37","author":"Moilanen","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0009","doi-asserted-by":"crossref","first-page":"e3877","DOI":"10.1210\/clinem\/dgac324","article-title":"Repeat bone mineral density screening measurement and fracture prediction in older men: a prospective cohort study","volume":"107","author":"Ensrud","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0010","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamainternmed.2020.2986","article-title":"Serial bone density measurement and incident fracture risk discrimination in postmenopausal women","volume":"180","author":"Crandall","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/jbmr.3194","article-title":"The ability of a single BMD and fracture history assessment to predict fracture over 25 years in postmenopausal women: the study of osteoporotic fractures","volume":"33","author":"Black","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jbmr.4444","article-title":"Characteristics of long-term femoral neck bone loss in postmenopausal women: a 25-year follow-up","volume":"37","author":"Moilanen","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0013","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1210\/jc.2014-3777","article-title":"Why does rate of bone density loss not predict fracture risk?","volume":"100","author":"Leslie","year":"2015","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.jocd.2023.101440_bib0014","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1385\/JCD:8:4:371","article-title":"Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the international society for clinical densitometry","volume":"8","author":"Baim","year":"2005","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2023.101440_bib0015","doi-asserted-by":"crossref","first-page":"e4267","DOI":"10.1210\/clinem\/dgac403","article-title":"How often should we measure bone density?","volume":"107","author":"Reid","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0016","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1359\/jbmr.090419","article-title":"Loss of hip BMD in older men: the osteoporotic fractures in men (MrOS) study","volume":"24","author":"Cawthon","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0017","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/jbmr.1671","article-title":"Change in hip bone mineral density and risk of subsequent fractures in older men","volume":"27","author":"Cawthon","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0018","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10654-009-9381-4","article-title":"Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women","volume":"24","author":"Bruyere","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jocd.2023.101440_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2017.02.012","article-title":"Time to clinically relevant fracture risk scores in postmenopausal women","volume":"130","author":"Gourlay","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0020","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1001\/jama.2021.9858","article-title":"Serial bone density measurement for osteoporosis screening","volume":"326","author":"Leslie","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0021","unstructured":"World Health Organization, C. C. f. M. B. D., University of Sheffield, UK FRAX: WHO fracture risk assessment tool. https:\/\/wwwsheffieldacuk\/FRAX\/."},{"key":"10.1016\/j.jocd.2023.101440_bib0022","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s001980170112","article-title":"The burden of osteoporotic fractures: a method for setting intervention thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0023","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","article-title":"Cost-effective osteoporosis treatment thresholds: the United States perspective","volume":"19","author":"Tosteson","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18954","article-title":"Reassessment intervals for transition from low to high fracture risk among adults older than 50 years","volume":"3","author":"Leslie","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jocd.2023.101440_bib0026","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00198-019-05106-3","article-title":"Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study","volume":"30","author":"Leslie","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0027","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/jbmr.4526","article-title":"The effect of fracture recency on observed 10-year fracture probability: a registry-based cohort study","volume":"37","author":"Leslie","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0028","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00198-010-1461-5","article-title":"Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement","volume":"22","author":"Leslie","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0029","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jocd.2011.05.014","volume":"14","author":"Leib","year":"2011","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2023.101440_bib0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jbmr.556","article-title":"FRAX underestimates fracture risk in patients with diabetes","volume":"27","author":"Giangregorio","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0031","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0032","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa1107142","article-title":"Bone-density testing interval and transition to osteoporosis in older women","volume":"366","author":"Gourlay","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0033","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.amepre.2015.11.015","article-title":"Time to osteoporosis and major fracture in older men: the MrOS study","volume":"50","author":"Gourlay","year":"2016","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0034","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","article-title":"BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures","volume":"18","author":"Stone","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0035","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00198-014-2728-z","article-title":"Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials","volume":"25","author":"Majumdar","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0036","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jocd.2021.11.009","article-title":"Poor Attendance for bone densitometry in patients at high risk of subsequent fragility fractures","volume":"25","author":"Sahota","year":"2022","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2023.101440_bib0037","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00198-010-1365-4","article-title":"Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results","volume":"22","author":"Brask-Lindemann","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0038","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocd.2023.101440_bib0039","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jocd.2023.101440_bib0040","doi-asserted-by":"crossref","DOI":"10.1097\/MOU.0000000000000101","article-title":"Androgen-deprivation-associated bone disease","volume":"24","author":"Skolarus","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.jocd.2023.101440_bib0041","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2012.11.007","article-title":"Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy","volume":"85","author":"Choo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jocd.2023.101440_bib0042","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/jbmr.3813","article-title":"Association of bone density monitoring in routine clinical practice with anti-osteoporosis medication use and incident fractures: a matched cohort study","volume":"34","author":"Leslie","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0043","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0044","doi-asserted-by":"crossref","first-page":"b2266","DOI":"10.1136\/bmj.b2266","article-title":"Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data","volume":"338","author":"Bell","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jocd.2023.101440_bib0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7326\/M15-2937","article-title":"Change in bone mineral density is an indicator of treatment-related antifracture effect in routine clinical practice: a registry-based cohort study","volume":"165","author":"Leslie","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0046","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1359\/JBMR.050814","article-title":"Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD","volume":"20","author":"Watts","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0047","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/jbmr.4333","article-title":"Patient outcomes in the years after a DXA-BMD treatment monitoring test: improved medication adherence in some, but too little too late","volume":"36","author":"Kline","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0048","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0049","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0050","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jocd.2023.101440_bib0051","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0052","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0053","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0054","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/jbmr.3996","article-title":"T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial","volume":"35","author":"Cosman","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0055","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0056","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/pst.123","article-title":"The relationship between osteoporotic fracture risk and a surrogate: apparent discrepancies between analyses based on individual patient data and summary statistics","volume":"3","author":"Barton","year":"2004","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jocd.2023.101440_bib0057","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1081\/BIP-120024209","article-title":"Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics","volume":"13","author":"Li","year":"2003","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.jocd.2023.101440_bib0058","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1001\/jamainternmed.2013.8998","article-title":"\u201cDue\u201d for a scan: examining the utility of monitoring densitometry","volume":"173","author":"Combs","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0059","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10546","article-title":"Romosozumab followed by antiresorptive treatment increases the probability of achieving bone mineral density treatment goals","volume":"5","author":"Cosman","year":"2021","journal-title":"JBMR Plus"},{"key":"10.1016\/j.jocd.2023.101440_bib0060","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0061","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0062","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0063","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0064","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00198-022-06495-8","article-title":"Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk","volume":"33","author":"Shin","year":"2022","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0065","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0066","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0067","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0068","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0069","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/S1590-8658(13)60351-5","article-title":"Prevalence of osteopenia and osteoporosis at the time of diagnosis in a series of adult celiac patients","volume":"45","author":"Usai Satta","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jocd.2023.101440_bib0070","first-page":"S203","article-title":"High risk of osteoporosis in patients with intestinal failure","volume":"35","author":"K\u00f8hler","year":"2016","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jocd.2023.101440_bib0071","doi-asserted-by":"crossref","DOI":"10.3390\/nu10070849","article-title":"A serological diagnosis of coeliac disease is associated with osteoporosis in older Australian adults","volume":"10","author":"Potter","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.jocd.2023.101440_bib0072","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s11695-019-03719-5","article-title":"Impact of bariatric surgery on bone mineral density: observational study of 110 patients followed up in a specialized center for the treatment of obesity in France","volume":"29","author":"Geoffroy","year":"2019","journal-title":"Obes Surg"},{"key":"10.1016\/j.jocd.2023.101440_bib0073","first-page":"S56","article-title":"Determining changes in bone metabolism after bariatric surgery in postmenopausal women","volume":"33","author":"Luhrs","year":"2019","journal-title":"Surg Endosc"},{"key":"10.1016\/j.jocd.2023.101440_bib0074","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1007\/s11695-021-05655-9","article-title":"Increased fracture risk after bariatric surgery: a case-controlled study with a long-term follow-up","volume":"31","author":"Alsaed","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.jocd.2023.101440_bib0075","first-page":"1","article-title":"Prevalence and influencing factors of spinal cord injury-related osteoporosis and fragility fractures in Thai people with chronic spinal cord injury: a cross-sectional, observational study","author":"Mahitthiharn","year":"2022","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0076","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jocd.2021.03.009","article-title":"S1 guidelines on bone impairment in spinal cord injury","volume":"24","author":"Dionyssiotis","year":"2021","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2023.101440_bib0077","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jocd.2019.07.012","article-title":"Bone mineral density testing in spinal cord injury: 2019 ISCD official position","volume":"22","author":"Morse","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2023.101440_bib0078","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0079","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1359\/jbmr.040116","article-title":"Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study","volume":"19","author":"McCloskey","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0080","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0081","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2023.101440_bib0082","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0083","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jocd.2023.101440_bib0084","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0085","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0086","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0087","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0088","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0089","doi-asserted-by":"crossref","first-page":"742","DOI":"10.7326\/0003-4819-136-10-200205210-00009","article-title":"Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial","volume":"136","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0091","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0092","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0093","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0094","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jc.2012-3680","article-title":"Treat-to-target for osteoporosis: is now the time?","volume":"98","author":"Lewiecki","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0095","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jocd.2023.101440_bib0096","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0097","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00198-010-1365-4","article-title":"Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results","volume":"22","author":"Brask-Lindemann","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0098","doi-asserted-by":"crossref","first-page":"990","DOI":"10.7326\/0003-4819-116-12-990","article-title":"Results of bone densitometry affect women's decisions about taking measures to prevent fractures","volume":"116","author":"Rubin","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0099","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jocd.2023.101440_bib0101","first-page":"105","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0102","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0103","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","author":"Bauer","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0104","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.jocd.2023.101440_bib0105","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1210\/jc.2014-1193","article-title":"A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring","volume":"99","author":"McNabb","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0106","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jbmr.3654","article-title":"Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension i trials","volume":"34","author":"Kim","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0107","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2023.101440_bib0108","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","author":"Bauer","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0109","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0110","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0111","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0112","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0113","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2023.101440_bib0115","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0116","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, Parallel Group Study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0117","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0118","doi-asserted-by":"crossref","first-page":"e3877","DOI":"10.1210\/clinem\/dgac324","article-title":"Repeat bone mineral density screening measurement and fracture prediction in older men: a Prospective Cohort Study","volume":"107","author":"Ensrud","year":"2022","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.jocd.2023.101440_bib0119","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamainternmed.2020.2986","article-title":"Serial bone density measurement and incident fracture risk discrimination in postmenopausal women","volume":"180","author":"Crandall","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0120","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jama.2013.277817","article-title":"Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture","volume":"310","author":"Berry","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0121","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jbmr.534","article-title":"Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN)","volume":"27","author":"Greendale","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0122","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa1107142","article-title":"Bone-density testing interval and transition to osteoporosis in older women","volume":"366","author":"Gourlay","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0123","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/jbmr.1671","article-title":"Change in hip bone mineral density and risk of subsequent fractures in older men","volume":"27","author":"Cawthon","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0124","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1210\/jc.2009-0417","article-title":"Sex hormones and frailty in older men: the osteoporotic fractures in men (MrOS) study","volume":"94","author":"Cawthon","year":"2009","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.jocd.2023.101440_bib0125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1359\/jbmr.081004","article-title":"Association between change in BMD and fragility fracture in women and men","volume":"24","author":"Berger","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0126","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00198-008-0562-x","article-title":"Natural history and risk factors for bone loss in postmenopausal Caucasian women: a 15-year follow-up population-based study","volume":"19","author":"Zhai","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0127","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archinte.167.2.155","article-title":"Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures","volume":"167","author":"Hillier","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0128","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1359\/JBMR.050704","article-title":"Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study","volume":"20","author":"Sornay-Rendu","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0129","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1359\/JBMR.050215","article-title":"Femoral neck bone loss predicts fracture risk independent of baseline BMD","volume":"20","author":"Nguyen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1359\/jbmr.2000.15.1.24","article-title":"Determinants of bone loss from the femoral neck in women of different ages","volume":"15","author":"Melton","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0131","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1359\/jbmr.1998.13.1.107","article-title":"Short-term and long-term fracture prediction by bone mass measurements: a prospective study","volume":"13","author":"Huang","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0132","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/jbmr.5650100206","article-title":"Spontaneous postmenopausal bone loss in different skeletal areas\u2013followed up for 15 years","volume":"10","author":"Hansen","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0133","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/bmj.309.6956.691","article-title":"Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study","volume":"309","author":"Jones","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.jocd.2023.101440_bib0134","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF02565127","article-title":"The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years","volume":"49","author":"G\u00e4rdsell","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0135","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0136","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2023.101440_bib0137","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0138","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00198-016-3736-y","article-title":"Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)","volume":"28","author":"Nakamura","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0139","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11657-019-0630-1","article-title":"Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India","volume":"14","author":"Sooragonda","year":"2019","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.jocd.2023.101440_bib0140","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0141","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0142","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0143","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen\/progestin interventions (PEPI) trial. The Writing Group for the PEPI","volume":"276","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0144","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.289.19.2525","article-title":"Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial","volume":"289","author":"Greenspan","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0145","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0146","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0147","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jocd.2023.101440_bib0148","series-title":"Preliminary Report","author":"Roman-Gonzalez","year":"2020"},{"key":"10.1016\/j.jocd.2023.101440_bib0149","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11657-018-0491-z","article-title":"Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study","volume":"13","author":"Silverman","year":"2018","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.jocd.2023.101440_bib0150","first-page":"150","article-title":"Real world experience of denosumab treatment in the belfast osteoporosis service","volume":"88","author":"Moran","year":"2019","journal-title":"Ulster Med J"},{"key":"10.1016\/j.jocd.2023.101440_bib0151","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2023.101440_bib0152","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0153","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00223-013-9777-8","article-title":"Once-weekly injection of low-dose teriparatide (28.2 \u03bcg) reduced the risk of vertebral fracture in patients with primary osteoporosis","volume":"94","author":"Fujita","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0154","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/jbmr.3067","article-title":"Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial","volume":"32","author":"Malouf-Sierra","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0155","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00223-019-00563-8","article-title":"Long-term effects of teriparatide followed by antiresorptive therapy on clinical outcomes in patients with severe spinal osteoporosis","volume":"105","author":"Oswald","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0156","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00198-020-05785-3","article-title":"Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis","volume":"32","author":"Saag","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2023.101440_bib0157","first-page":"34","article-title":"Comparison of BMD changes and bone formation marker levels 3 years after bisphosphonate discontinuation: FLEX and HORIZON-PFT extension I trials","author":"Kim","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0158","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0159","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/jbmr.1864","article-title":"BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate","volume":"28","author":"McNabb","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0160","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment the fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2023.101440_bib0161","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the fracture intervention trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0162","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2023.101440_bib0163","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2023.101440_bib0164","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"}],"updated-by":[{"DOI":"10.1016\/j.jocd.2024.101540","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000}}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695023000902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695023000902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:45:07Z","timestamp":1761083107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094695023000902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":164,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1094695023000902"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2023.101440","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follow-up Bone Mineral Density Testing: 2023 Official Positions of the International Society for Clinical Densitometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2023.101440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The International Society for Clinical Densitometry. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101440"}}